What the research shows

Two placebo-controlled studies in healthy adults measured growth hormone and insulin-like growth factor 1 (IGF-1) after a subcutaneous preparation. Concentrations increased and remained elevated for days. The endpoints were hormone levels, so the trials do not establish changes in strength, body composition or long-term health. Read the original studies in healthy adults.

A separate experiment collected repeated blood samples to examine pulses of growth hormone after CJC-1295. This design distinguished changes in baseline hormone levels from the rhythm of secretion. Read the pulsatility study.

Documented formats

The published experiments used the long-acting, albumin-binding version. A label reading “without DAC” points to a different preparation and needs its own identity record and evidence.

Testing and purity

Verify whether the albumin-binding modification is present. A certificate reporting only the base peptide sequence or only an HPLC percentage leaves this defining structural feature unresolved.

How to read a batch report

Questions about CJC-1295

What does DAC mean here?

Drug affinity complex refers to the modification used to bind the peptide to a blood protein. It matters when comparing how long study material stays in circulation.

Why did the researchers measure IGF-1 as well?

IGF-1 responds to growth hormone signaling. Measuring both allowed researchers to follow an immediate hormone response and a downstream marker.